Abstract
Forty patients with multiple myeloma scheduled to receive melphalan 200 mg/m2 followed by autologous stem cell transplantation were randomly assigned to receive oral cryotherapy or room temperature normal saline rinses 30 min before and for 6 h after high-dose therapy. Patients were evaluated for the development of mucositis using the National Cancer Institute grading system as well as evaluation of secondary measures such as days of total parenteral nutrition (TPN), narcotic use, hospitalization, weight loss and resumption of oral caloric intake for 28 days after transplant. Patients self-scored their pain, swallowing, drinking, eating, sleeping and taste alterations for 28 days. The primary end point of this trial was the incidence of grades 3–4 mucositis. Compared to the normal saline group, patients using cryotherapy experienced less grade 3–4 mucositis, 14 vs 74%, P=0.0005. Patients receiving cryotherapy also had statistically lower uses of narcotics and TPN, although there were no differences in length of hospitalization or weight loss. Patient-reported pain was significantly lower and activities were significantly better in the cryotherapy group.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sonis ST . Oral mucositis in cancer therapy (Review). J Support Oncol 2004; 2: 3–8.
Cawley MM, Benson LM . Current trends in managing oral mucositis (Review). Clin J Oncol Nurs 2005; 9: 584–592.
Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T . The effect of oral mucositis on morbidity and mortality in bone marrow transplant (Review). Semin Oncol 2003; 30: 76–83.
Moreau P, Facon T, Attal M, Hulin, Michallet M, Maloisel F et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99: 731–735.
Bensinger WI . The role of hematopoietic stem cell transplantation in the treatment of multiple myeloma. J Natl Cooperative Cancer Network 2004; 2: 371–378.
Filicko J, Lazarus HM, Flomenberg N . Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment (Review). Bone Marrow Transplant 2003; 31: 1–10.
Cowen D, Tardieu C, Schubert M, Peterson D, Resbeut M, Faucher C et al. Low energy Helium–Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997; 38: 697–703.
Spencer A, Horvath N, Gibson J, Prince HM, Herrmann R, Bashford J et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971–977.
Mahood DJ, Dose AM, Loprinzi CL, Veeder MH, Athmann LM, Therneau TM et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol 1991; 9: 449–452.
Rocke LK, Loprinzi CL, Lee JK, Kunselman SJ, Iverson RK, Finck G et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993; 72: 2234–2238.
Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F . Ice pops to prevent melphalan-induced stomatitis. Lancet 1996; 347: 1691–1692.
Dumontet C, Sonnet A, Baston Y, Salles G, Espinouse D, Coiffier B . Prevention of high dose L-PAM-induced mucositis by cryotherapy. Bone Marrow Transplant 1994; 14: 492–494.
Avritscher EB, Cooksley CD, Elting LS . Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis (Review). Semin Oncol Nurs 2004; 20: 3–10.
Pinguet F, Martel P, Fabbro M, Petit I, Canal P, Culine S et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997; 17: 605–611.
Barasch A, Peterson DE, Tanzer JM, D'Ambrosio JA, Nuki K, Schubert M et al. Helium–neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 1995; 76: 2550–2556.
Aquino VM, Harvey AR, Garvin JH, Godder KT, Nieder ML, Adams RH et al. A double-blind randomized placebo-controlled study of oral glutamine in the prevention of mucositis in children undergoing hematopoietic stem cell transplantation: a pediatric blood and marrow transplant consortium study. Bone Marrow Transplant 2005; 36: 611–616.
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.
Acknowledgements
This work was supported by Friends of Jose Carreras International Leukemia Foundation Presidential Award, NCI P01 CA-18029.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lilleby, K., Garcia, P., Gooley, T. et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37, 1031–1035 (2006). https://doi.org/10.1038/sj.bmt.1705384
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705384
Keywords
This article is cited by
-
Protective effect of cryotherapy against oral mucositis among allogeneic hematopoietic stem cell transplant recipients using melphalan-based conditioning
Supportive Care in Cancer (2023)
-
Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial
BMC Medicine (2022)
-
Oral cryotherapy for management of chemotherapy‐induced oral mucositis in haematopoietic cell transplantation: a systematic review
BMC Cancer (2022)
-
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Bone Marrow Transplantation (2022)
-
Photobiomodulation: a promising innovative approach for preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation
Supportive Care in Cancer (2022)